Mereo BioPharma Group plc Sponsored ADR Stock

$2.78

4.91% yesterday

Nasdaq, Jun 12, 10:00 pm CET

ISIN

US5894921072

Symbol

MREO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Mereo BioPharma Group plc Sponsored ADR Stock price

$2.78

-0.02 0.71% 5Y

Nasdaq, Closing price Thu, Jun 12 2025

+0.13 4.91%

ISIN

US5894921072

Symbol

MREO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$421.35m
Enterprise Value	$358.87m
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	36.77
Free Cash Flow (TTM) Free Cash Flow	$-33.49m
Cash position	$62.48m
P/E forward	negative
P/S forward	11.10
EV/Sales forward	9.46
Short interest	7.45%

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Get Started for Free Today

Mereo BioPharma Group plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

9x Buy

100%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Mereo BioPharma Group plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	26 26	12% 12% -
- Research and Development Expense	21 21	23% 23% -
EBITDA	-46 -46	7% 7% -
- Depreciation and Amortization	1.09 1.09	3% 3% -
EBIT (Operating Income) EBIT	-47 -47	7% 7% -
Net Profit	-43 -43	0% 0% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Mereo BioPharma Group plc Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

about one month ago

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the fi...

Neutral

GlobeNewsWire

●

3 months ago

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025

Positive

MarketBeat

●

3 months ago

Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential

Stocks priced under $10 present an attractive entry point into the market for investors seeking to maximize portfolio diversification and growth potential without a significant upfront capital outlay. These affordable equities allow investors to acquire a larger number of shares for a given investment and can yield substantial percentage gains.

More Mereo BioPharma Group plc Sponsored ADR News

Company Profile

Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Denise Scots-Knight
Employees	33
Founded	2015
Website	www.mereobiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now